Evaluation of performance testing of different rapid diagnostic kits in comparison with EIAs to validate detection of hepatitis B virus among high risk group in Nigeria

Afolabi, Abosede Yetunde; Bakarey, Adeleye Solomon; Adewumi, Moses Olubusuyi

doi:10.1080/15321819.2018.1458238

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study in Mongolia [ 72 ] which tested 19 commercially available HBsAg POCs using a serum sample showed the average sensitivity and specificity being 100% and 99%, respectively. Whilst most HBsAg POCs of various brands have shown promising clinical performance [ 35 , 38 , 67 , 70 , 73 ], available validation data are limited and further studies with large sample size and in diverse populations including different ethnicity and hepatitis B prevalence populations and people living with HIV are needed.…”

Section: Poc Tests For Hepatitis B and Their Clinical Performancementioning

confidence: 99%

“…Although many studies of different HBsAg POCs showed very good sensitivity [ 31 , 38 , 73 ], false negativity is still among the biggest concerns: Around one in ten negative test results on average could be HBsAg positive [ 31 ]. Most cases with false negative results were reported to have low titres of HBsAg, such as in studies using Determine/Vikia HBsAg POCs, where most false negative cases had HBsAg titres lower than 30 IU/mL [ 32 , 33 ].…”

Section: Poc Tests For Hepatitis B and Their Clinical Performancementioning

confidence: 99%

See 1 more Smart Citation

Point-of-Care Tests for Hepatitis B: An Overview

Xiao

Thompson

Howell

2020

Cells

View full text Add to dashboard Cite

Despite the heavy disease burden posed by hepatitis B, around 90% of people living with hepatitis B are not diagnosed globally. Many of the affected populations still have limited or no access to essential blood tests for hepatitis B. Compared to conventional blood tests which heavily rely on centralised laboratory facilities, point-of-care testing for hepatitis B has the potential to broaden testing access in low-resource settings and to engage hard-to-reach populations. Few hepatitis B point-of-care tests have been ratified for clinical use by international and regional regulatory bodies, and countries have been slow to adopt point-of-care testing into hepatitis B programs. This review presents currently available point-of-care tests for hepatitis B and their roles in the care cascade, reviewing evidence for testing performance, utility, acceptability, costs and cost-effectiveness when integrated into hepatitis B diagnosis and monitoring programs. We further discuss challenges and future directions in aspects of technology, implementation, and regulation when adopting point-of-care testing in hepatitis B programs.

show abstract

Section: Poc Tests For Hepatitis B and Their Clinical Performancementioning

confidence: 99%

Section: Poc Tests For Hepatitis B and Their Clinical Performancementioning

confidence: 99%

Point-of-Care Tests for Hepatitis B: An Overview

Xiao

Thompson

Howell

2020

Cells

View full text Add to dashboard Cite

show abstract

Artificial Intelligence in Rural Health in Developing Countries

Mondal

Singla

2023

Medical Virology: From Pathogenesis to Disease Control

View full text Add to dashboard Cite

Hepatitis B virus infection among men who have sex with men and transgender women living with or at risk for HIV: a cross sectional study in Abuja and Lagos, Nigeria

et al. 2021

View full text Add to dashboard Cite

Background Despite the development of a safe and efficacious hepatitis B vaccine in 1982, the hepatitis B virus (HBV) remains a public health burden in sub-Saharan Africa. Due to shared risk factors for virus acquisition, men who have sex with men (MSM) and transgender women (TGW) living with HIV are at increased risk of HBV. We estimated the prevalence of HBV and associated factors for MSM and TGW living with or without HIV in Nigeria. Methods Since March 2013, TRUST/RV368 has recruited MSM and TGW in Abuja and Lagos, Nigeria using respondent driven sampling. Participants with HIV diagnosis, enrollment as of June 2015, and available plasma were selected for a cross-sectional study and retrospectively tested for hepatitis B surface antigen and HBV DNA. Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for factors associated with prevalent HBV infection. Results A total of 717 MSM and TGW had a median age of 25 years (interquartile range [IQR]: 21–27), 5% self-reported HBV vaccination, 61% were living with HIV, 10% had prevalent HBV infection and 6% were HIV-HBV co-infected. HIV mono-infected as compared to HIV-HBV co-infected had a higher median CD4 T cell count [425 (IQR: 284–541) vs. 345 (IQR: 164–363) cells/mm3, p = 0.03] and a lower median HIV RNA viral load [4.2 (IQR: 2.3–4.9) vs. 4.7 (IQR: 3.9–5.4) log10copies/mL, p < 0.01]. The only factor independently associated with HBV was self-report of condomless sex at last anal intercourse (OR: 2.2, 95% CI: 1.3, 3.6). HIV infection was not independently associated with HBV (OR: 1.0, 95% CI: 0.7–1.6). Conclusion HBV prevalence was moderately high but did not differ by HIV in this cohort of MSM and TGW. Recent condomless sex was associated with elevated HBV risk, reinforcing the need to increase communication and education on condom use among key populations in Nigeria. Evaluating use of concurrent HIV antiretroviral therapy with anti-HBV activity may confirm the attenuated HBV prevalence for those living with HIV.

show abstract

Evaluation of performance testing of different rapid diagnostic kits in comparison with EIAs to validate detection of hepatitis B virus among high risk group in Nigeria

Cited by 3 publications

References 13 publications

Point-of-Care Tests for Hepatitis B: An Overview

Point-of-Care Tests for Hepatitis B: An Overview

Artificial Intelligence in Rural Health in Developing Countries

Hepatitis B virus infection among men who have sex with men and transgender women living with or at risk for HIV: a cross sectional study in Abuja and Lagos, Nigeria

Contact Info

Product

Resources

About